Hexarelin
A synthetic growth hormone–releasing peptide studied in early clinical research; not FDA-approved.
What it is
Hexarelin is among the most potent of the classic growth-hormone-releasing peptides, studied in the 1990s for GH release and, intriguingly, for direct cardiac effects that briefly made it a heart-research candidate.
Early human studies exist, but development stalled decades ago — partly because its strong GH stimulation shows desensitization with repeated use, and it nudges cortisol and prolactin more than its politer siblings. Never approved anywhere; prohibited in tested sport.
What researchers have actually studied it for
Growth-hormone release and cardiovascular effects in early clinical research from the 1990s; development never progressed to approval.
How it works
A six-amino-acid ghrelin-receptor agonist — the strongest acute GH releaser of the classic GHRP family in comparative studies. It also binds CD36, a receptor on heart and vascular tissue, the basis of its separate cardioprotective research thread.
The molecule itself
A hexapeptide GHRP-family ghrelin agonist, structurally close to GHRP-6 with a methylated tryptophan boosting potency — the family's strongest acute GH releaser in comparative studies. It also binds CD36 on cardiac tissue, a second receptor unrelated to growth hormone entirely.
Where it came from
Synthesized in the early 1990s in the GHRP wave that followed ghrelin-pathway discoveries, hexarelin generated genuine academic interest — including small human studies on cardiac function — before receptor desensitization and industry pivots shelved it. It persists as gray-market inventory with a vintage literature.
The timeline
early 1990s
Synthesized in the GHRP wave; potency documented against siblings.
1990s
Small human studies explore GH release and, separately, cardiac contractility via CD36.
2000s
Desensitization findings and industry pivots end development.
What the research record actually contains
- 1990s human pharmacology: potent acute GH release, with documented attenuation over weeks of repeated dosing.
- Small human and animal studies on cardiac contractility and ischemia via CD36 — never advanced.
- No controlled trials on body composition or any marketed wellness outcome.
What could change this assessment
Scientifically closed — no programs, no trials, a vintage literature. Its CD36 thread occasionally resurfaces academically, which is the only development worth watching and has nothing to do with wellness use.
What's known about risks
Beyond acute-study tolerability, unknowns dominate: its cortisol/prolactin nudge, receptor desensitization, and untested chronic use. The cardiac binding cuts both ways — interesting mechanism, uncharacterized long-term meaning.
Where it stands legally
Never approved; research-chemical channel only. Prohibited in tested competition.
Worth asking a licensed provider
- 1.If GH-axis therapy is the goal, why this shelved compound over options with active medical use?
- 2.What does receptor desensitization mean for any sustained plan?
- 3.What monitoring would make sense given its broader hormonal footprint?
Common claims, corrected
“Strongest GHRP means best results.”
Reality: Its potency comes with the family's worst desensitization and broadest hormonal spillover — 'strongest' and 'most sustainable' point opposite directions here.
“The cardiac research means heart benefits.”
Reality: Small exploratory studies on contractility were never advanced; an uncharacterized cardiac receptor interaction is a question mark, not a feature.
Hexarelin FAQ
Is hexarelin stronger than other GHRPs?
On acute GH release, early studies rank it among the strongest — with more receptor desensitization over time and more effect on cortisol and prolactin. 'Strongest' and 'best-behaved' are different categories.
What's the story with hexarelin and the heart?
Small studies explored direct cardioprotective effects through non-GH receptors — a genuinely interesting thread that was never carried into a full clinical program.
Is hexarelin banned in sports?
Yes — GH secretagogues are prohibited in tested competition.
Why did hexarelin lose to ipamorelin commercially?
Receptor desensitization and cortisol/prolactin spillover made it the family's bluntest instrument; the wellness market chose the politer sibling.
Is hexarelin's potency measurable in outcomes?
Only in GH-release curves — no outcome trial exists for it or any family member. Potency at releasing a hormone is not potency at anything you'd buy it for.